KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-cash Items (2018 - 2019)

Amneal Pharmaceuticals has reported Non-cash Items over the past 2 years, most recently at $2.1 million for Q4 2019.

  • Quarterly results put Non-cash Items at $2.1 million for Q4 2019, down 20.3% from a year ago — trailing twelve months through Dec 2019 was $2.1 million (down 20.3% YoY), and the annual figure for FY2019 was $2.1 million, down 20.3%.
  • Non-cash Items for Q4 2019 was $2.1 million at Amneal Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Over the last five years, Non-cash Items for AMRX hit a ceiling of $2.6 million in Q4 2018 and a floor of $2.1 million in Q4 2019.